These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 33631986)

  • 21. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.
    Schweizer MT; Zhou XC; Wang H; Bassi S; Carducci MA; Eisenberger MA; Antonarakis ES
    Eur Urol; 2014 Oct; 66(4):646-52. PubMed ID: 24491307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis.
    Mori K; Miura N; Mostafaei H; Quhal F; Sari Motlagh R; Pradere B; Kimura S; Kimura T; Egawa S; Briganti A; Karakiewicz PI; Shariat SF
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):539-548. PubMed ID: 32152435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV Study.
    Wallis CJD; Satkunasivam R; Saskin R; Bansal S; Kulkarni GS; Emmenegger U; Nam RK
    Urology; 2018 Mar; 113():138-145. PubMed ID: 29191639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
    Conteduca V; Caffo O; Fratino L; Lo Re G; Basso U; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Zagonel V; Veccia A; Lolli C; Maines F; De Giorgi U
    Future Oncol; 2015; 11(21):2881-91. PubMed ID: 26436290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
    Suzuki H; Castellano D; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Foster MC; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
    Jpn J Clin Oncol; 2021 Aug; 51(8):1287-1297. PubMed ID: 33738495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis.
    Perletti G; Monti E; Marras E; Cleves A; Magri V; Trinchieri A; Rennie PS
    Arch Ital Urol Androl; 2015 Jul; 87(2):121-9. PubMed ID: 26150028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis.
    Marchioni M; Di Nicola M; Primiceri G; Novara G; Castellan P; Paul AK; Veccia A; Autorino R; Cindolo L; Schips L
    J Urol; 2020 Apr; 203(4):751-759. PubMed ID: 31689158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer.
    Mori K; Kimura T; Onuma H; Kimura S; Yamamoto T; Sasaki H; Miki J; Miki K; Egawa S
    Prostate; 2017 Jul; 77(10):1144-1150. PubMed ID: 28557065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in the management of castration resistant prostate cancer.
    Ritch CR; Cookson MS
    BMJ; 2016 Oct; 355():i4405. PubMed ID: 27754846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
    Lebdai S; Basset V; Branchereau J; de La Taille A; Flamand V; Lebret T; Murez T; Neuzillet Y; Ploussard G; Audenet F
    World J Urol; 2016 May; 34(5):617-24. PubMed ID: 26373956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?
    Andrews JR; Ahmed ME; Karnes RJ; Kwon E; Bryce AH
    Prostate; 2020 Apr; 80(5):399-406. PubMed ID: 31943289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
    Thiery-Vuillemin A; Poulsen MH; Lagneau E; Ploussard G; Birtle A; Dourthe LM; Beal-Ardisson D; Pintus E; Trepiakas R; Lefresne F; Lukac M; Van Sanden S; Pissart G; Reid A;
    Eur Urol; 2020 Mar; 77(3):380-387. PubMed ID: 31594705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
    Ito K; Kimura T; Onuma H; Tabata R; Shimomura T; Miki K; Tomita M; Egawa S
    Prostate; 2018 May; 78(7):498-505. PubMed ID: 29473179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study.
    Naito Y; Kato M; Kawanishi H; Yuguchi Y; Yuba T; Ishikawa T; Hattori K; Yamamoto A; Sano T; Matsukawa Y; Kimura T; Nishikimi T; Hattori R; Tsuzuki T; Gotoh M
    Prostate; 2020 Nov; 80(15):1373-1380. PubMed ID: 32914895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer.
    Graff JN; Liang LW; Kim J; Stenzl A
    Future Oncol; 2021 Aug; 17(23):3017-3026. PubMed ID: 34044584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
    J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide.
    Nakai Y; Tanaka N; Miyake M; Inoue T; Anai S; Fujimoto K
    BMC Res Notes; 2018 May; 11(1):342. PubMed ID: 29843816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer.
    Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
    Clin Genitourin Cancer; 2018 Apr; 16(2):142-148. PubMed ID: 29042308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.